tetano
Editor, Senior Moderator
Tumori
. 2021 Dec 29;3008916211067825.
doi: 10.1177/03008916211067825. Online ahead of print.
Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?
Giovanna Gattuso[SUP] 1 [/SUP], Elisabetta Schiavello[SUP] 1 [/SUP], Chiara Oltolini[SUP] 2 [/SUP], Veronica Biassoni[SUP] 1 [/SUP], Monica Terenziani[SUP] 1 [/SUP], Stefano Chiaravalli[SUP] 1 [/SUP], Marta Giorgia Podda[SUP] 1 [/SUP], Cristina Meazza[SUP] 1 [/SUP], Roberto Luksch[SUP] 1 [/SUP], Andrea Ferrari[SUP] 1 [/SUP], Michela Casanova[SUP] 1 [/SUP], Giovanna Sironi[SUP] 1 [/SUP], Luca Bergamaschi[SUP] 1 [/SUP], Nadia Puma[SUP] 1 [/SUP], Filippo Spreafico[SUP] 1 [/SUP], Maura Massimino[SUP] 1 [/SUP]
Affiliations
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, oncologists have managed patients at higher risk of having a severe course of this infection. This raises new questions about their correct management, as well as the difficulty of distinguishing tumor/treatments complications from those related to COVID-19. We report a case of an 11-year-old boy undergoing treatment for T-cell lymphoblastic lymphoma who experienced a prolonged COVID-19 course. Oncologic therapy was continued without significant changes compared to the initially planned treatment. No relevant complications occurred. COVID-19 convalescent plasma was administered, resulting in a positive antibody titer after 24 days.
Keywords: COVID-19; lymphoma; prolonged infection; treatments.
. 2021 Dec 29;3008916211067825.
doi: 10.1177/03008916211067825. Online ahead of print.
Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?
Giovanna Gattuso[SUP] 1 [/SUP], Elisabetta Schiavello[SUP] 1 [/SUP], Chiara Oltolini[SUP] 2 [/SUP], Veronica Biassoni[SUP] 1 [/SUP], Monica Terenziani[SUP] 1 [/SUP], Stefano Chiaravalli[SUP] 1 [/SUP], Marta Giorgia Podda[SUP] 1 [/SUP], Cristina Meazza[SUP] 1 [/SUP], Roberto Luksch[SUP] 1 [/SUP], Andrea Ferrari[SUP] 1 [/SUP], Michela Casanova[SUP] 1 [/SUP], Giovanna Sironi[SUP] 1 [/SUP], Luca Bergamaschi[SUP] 1 [/SUP], Nadia Puma[SUP] 1 [/SUP], Filippo Spreafico[SUP] 1 [/SUP], Maura Massimino[SUP] 1 [/SUP]
Affiliations
- PMID: 34965799
- DOI: 10.1177/03008916211067825
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, oncologists have managed patients at higher risk of having a severe course of this infection. This raises new questions about their correct management, as well as the difficulty of distinguishing tumor/treatments complications from those related to COVID-19. We report a case of an 11-year-old boy undergoing treatment for T-cell lymphoblastic lymphoma who experienced a prolonged COVID-19 course. Oncologic therapy was continued without significant changes compared to the initially planned treatment. No relevant complications occurred. COVID-19 convalescent plasma was administered, resulting in a positive antibody titer after 24 days.
Keywords: COVID-19; lymphoma; prolonged infection; treatments.